Search by Drug Name or NDC

NDC 51655-0915-52 terazosin 2 mg/1 Details

terazosin 2 mg/1

terazosin is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Northwind Pharmaceuticals, LLC. The primary component is TERAZOSIN HYDROCHLORIDE.

MedlinePlus Drug Summary

Terazosin is used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia or BPH), which include difficulty urinating (hesitation, dribbling, weak stream, and incomplete bladder emptying), painful urination, and urinary frequency and urgency. It also is used alone or in combination with other medications to treat high blood pressure. Terazosin is in a class of medications called alpha-blockers. It relieves the symptoms of BPH by relaxing the muscles of the bladder and prostate. It lowers blood pressure by relaxing the blood vessels so that blood can flow more easily through the body. High blood pressure is a common condition, and when not treated it can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.

Related Packages: 51655-0915-52
Last Updated: 04/21/2024
MedLinePlus Full Drug Details: Terazosin

Product Information

NDC	51655-0915
Product ID	51655-915_ff0e0009-8baf-e0eb-e053-6294a90afa82
Associated GPIs
GCN Sequence Number	n/a
GCN Sequence Number Description	n/a
HIC3	n/a
HIC3 Description	n/a
GCN	n/a
HICL Sequence Number	n/a
HICL Sequence Number Description	n/a
Brand/Generic	n/a
Proprietary Name	terazosin
Proprietary Name Suffix	n/a
Non-Proprietary Name	terazosin
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	CAPSULE
Route	ORAL
Active Ingredient Strength	2
Active Ingredient Units	mg/1
Substance Name	TERAZOSIN HYDROCHLORIDE
Labeler Name	Northwind Pharmaceuticals, LLC
Pharmaceutical Class	Adrenergic alpha-Antagonists [MoA], alpha-Adrenergic Blocker [EPC]
DEA Schedule	n/a
Marketing Category	ANDA
Application Number	ANDA075614
Listing Certified Through	2024-12-31

Package

NDC 51655-0915-52 (51655091552)

Pricing Information	N/A
NDC Package Code	51655-915-52
Billing NDC	51655091552
Package	30 CAPSULE in 1 BOTTLE, PLASTIC (51655-915-52)
Marketing Start Date	2023-06-26
NDC Exclude Flag	N